Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors.
Yoneda S, Imagawa A, Hosokawa Y, Baden MY, Kimura T, Uno S, Fukui K, Goto K, Uemura M, Eguchi H, Iwahashi H, Kozawa J, Shimomura I. Yoneda S, et al. Among authors: uemura m. Diabetes Care. 2019 Jul;42(7):e116-e118. doi: 10.2337/dc18-2518. Epub 2019 May 10. Diabetes Care. 2019. PMID: 31076419 No abstract available.
A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma.
Kato T, Tomiyama E, Koh Y, Matsushita M, Hayashi Y, Nakano K, Ishizuya YU, Wang C, Hatano K, Kawashima A, Ujike T, Kawasaki K, Morii E, Gotoh K, Eguchi H, Kiyotani K, Fujita K, Nonomura N, Uemura M. Kato T, et al. Among authors: uemura m. Anticancer Res. 2020 Sep;40(9):4875-4883. doi: 10.21873/anticanres.14490. Anticancer Res. 2020. PMID: 32878775
Inflammatory Cell Infiltration Into Islets Without PD-L1 Expression Is Associated With the Development of Immune Checkpoint Inhibitor-Related Type 1 Diabetes in Genetically Susceptible Patients.
Kawata S, Kozawa J, Yoneda S, Fujita Y, Kashiwagi-Takayama R, Kimura T, Hosokawa Y, Baden MY, Uno S, Uenaka R, Namai K, Koh Y, Tomimaru Y, Hirata H, Uemura M, Nojima S, Morii E, Eguchi H, Imagawa A, Shimomura I. Kawata S, et al. Among authors: uemura m. Diabetes. 2023 Apr 1;72(4):511-519. doi: 10.2337/db22-0557. Diabetes. 2023. PMID: 36657987 Free PMC article.
Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
Kato T, Nagahara A, Kawamura N, Nakata W, Soda T, Matsuzaki K, Hatano K, Kawashima A, Ujike T, Imamura R, Nishimura K, Takada S, Tsujihata M, Yamaguchi S, Takao T, Nakai Y, Nakayama M, Nonomura N, Uemura M. Kato T, et al. Among authors: uemura m. Anticancer Res. 2021 Nov;41(11):5811-5816. doi: 10.21873/anticanres.15398. Anticancer Res. 2021. PMID: 34732455
Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma.
Koh Y, Nakano K, Katayama K, Yamamichi G, Yumiba S, Tomiyama E, Matsushita M, Hayashi Y, Yamamoto Y, Kato T, Hatano K, Kawashima A, Ujike T, Imamura R, Yamaguchi R, Imoto S, Shiotsu Y, Nonomura N, Uemura M. Koh Y, et al. Among authors: uemura m. Int J Urol. 2022 May;29(5):462-469. doi: 10.1111/iju.14816. Epub 2022 Feb 19. Int J Urol. 2022. PMID: 35184335 Free PMC article.
1,258 results